Neurogene Inc. (UU8.SG)
Stuttgart · EUR · Healthcare · Biotechnology
€24.80 (+18.10%) as of
Key statistics
- Market cap
- 496.28M
- EPS (TTM)
- -4.36
- Dividend yield
- 0.00%
- 52-week range
- 13.39 – 35.80
- Beta
- 2.09
- Profit margin
- 0.00%
- Volume
- 80.00
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 131
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.